Clinical observations of platelet aggregation in patients with type II diabetes undergoing percutaneous coronary intervention with clopidogrel treatment

AIM: To examine clopidogrel resistance among patients with type II diabetes undergoing percutaneous coronary intervention (PCI) on clopidogrel treatment. METHODS: Forty six patients (11 diabetic and 35 nondiabetic patients) with acute coronary syndrome (ACS) who had undergone PCI were treated with clopidogrel (300 mg loading dose followed by a dose of 75 mg/day). Platelet aggregation function was assessed before and 2, 4, 6, 24, 48 and 30 days after clopidogrel treatment. Platelet aggregation and characteristics between groups were compared. RESULTS: The ratio of clopidogrel resistance was much higher in diabetic patients (55%) than in nondiabetic patients (26%) (P<0.05). CONCLUSION: Diabetic subjects undergoing PCI have a higher ratio of clopidogrel resistance compared with nondiabetic subjects.